Tokyo Tape
Sign in
← H.U. Group Holdings

Half-year report · Q2

4544.TEDINET S100UPH6
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥120.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥236.9bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥116.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥956m2024-04-01 → 2024-09-30Cons.Operating income
Operating income−¥1.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥1.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income−¥7.2bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.6bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥1.6bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax−¥1.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥821m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥821m2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥291.4bnat 2024-09-30Cons.Assets
Total assets¥290.8bnat 2024-03-31Cons.Assets
Total assets¥284.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥155.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥148.3bnat 2024-03-31Cons.Liabilities
Net assets / equity¥136.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥142.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥150.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥47.0bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥39.9bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥47.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥39.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.6bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥9.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥16.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥10.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-14.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-132.772023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio46.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio49.0%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio52.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥2.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥76.7bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥76.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥205m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥31.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥29.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2024-04-01 → 2024-09-30¥14.5bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2024-04-01 → 2024-09-30¥14.4bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥9m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2024-04-01 → 2024-09-30¥879m
—segment totalrevenue2024-04-01 → 2024-09-30¥122.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥120.0bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.4bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.5bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥2.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥72.4bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥72.3bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥74m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥6.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥33.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-09-30¥564m
—segment totalrevenue2023-04-01 → 2023-09-30¥119.6bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥116.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 536
ItemContextValueUnit
Net assetsPrior1YearInstant142505000000JPY
Net assetsCurrentQuarterInstant136080000000JPY
Liabilities and net assetsPrior1YearInstant290849000000JPY
Liabilities and net assetsCurrentQuarterInstant291371000000JPY
Net salesPrior1YTDDuration116543000000JPY
Net salesCurrentYTDDuration119987000000JPY
Cost of salesPrior1YTDDuration84968000000JPY
Cost of salesCurrentYTDDuration87299000000JPY
Gross profitPrior1YTDDuration31575000000JPY
Gross profitCurrentYTDDuration32687000000JPY
Selling general and administrative expensesPrior1YTDDuration33144000000JPY
Selling general and administrative expensesCurrentYTDDuration31731000000JPY
Operating incomePrior1YTDDuration-1569000000JPY
Operating incomeCurrentYTDDuration956000000JPY
Interest income noiPrior1YTDDuration212000000JPY
Interest income noiCurrentYTDDuration249000000JPY
Dividends income noiPrior1YTDDuration63000000JPY
Dividends income noiCurrentYTDDuration40000000JPY
Foreign exchange gains noiPrior1YTDDuration1096000000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration192000000JPY
Other noiCurrentYTDDuration178000000JPY
Non operating incomePrior1YTDDuration1564000000JPY
Non operating incomeCurrentYTDDuration468000000JPY
Interest expenses noePrior1YTDDuration195000000JPY
Interest expenses noeCurrentYTDDuration238000000JPY
Equity in losses of affiliates noePrior1YTDDuration743000000JPY
Equity in losses of affiliates noeCurrentYTDDuration617000000JPY
Loss on investments in capital noePrior1YTDDuration406000000JPY
Loss on investments in capital noeCurrentYTDDuration265000000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration1167000000JPY
Other noePrior1YTDDuration221000000JPY
Other noeCurrentYTDDuration393000000JPY
Non operating expensesPrior1YTDDuration1567000000JPY
Non operating expensesCurrentYTDDuration2682000000JPY
Ordinary incomePrior1YTDDuration-1571000000JPY
Ordinary incomeCurrentYTDDuration-1257000000JPY
Gain on transfer of business eiPrior1YTDDuration377000000JPY
Gain on transfer of business eiCurrentYTDDuration－JPY
Reversal of provision for compensation loss elPrior1YTDDuration－JPY
Reversal of provision for compensation loss elCurrentYTDDuration678000000JPY
Other eiPrior1YTDDuration0JPY
Other eiCurrentYTDDuration3000000JPY
Extraordinary incomePrior1YTDDuration377000000JPY
Extraordinary incomeCurrentYTDDuration681000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration15000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration125000000JPY
Loss on valuation of investment securities elPrior1YTDDuration279000000JPY
Loss on valuation of investment securities elCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass